Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.78 |
| ▸ | MAOA | P21397 | 13/20 | 0.78 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31557837 | 0.89 | MAOB (0.78) | MAOBMAOACREBBP | |
| SCHEMBL5637277 | 0.89 | MAOB (0.78) | MAOBMAOACREBBP | |
| SCHEMBL7406456 | 0.88 | MAOB (0.62) | MAOBMAOACREBBPAKT1 | |
| SCHEMBL2236580 | 0.87 | MAOB (1.00) | MAOBMAOACREBBP | |
| SCHEMBL30645772 | 0.82 | MAOB (0.67) | MAOBMAOACREBBP | |
| SCHEMBL28355190 | 0.81 | MAOB (0.66) | MAOBMAOACREBBPPDE3BPDE3A | |
| SCHEMBL11089929 | 0.79 | EIF2AK2 (0.63) | MAOBMAOAPDE3BPDE3A | |
| SCHEMBL689457 | 0.79 | MAOB (0.62) | MAOBMAOAPDE3BPDE3A | |
| SCHEMBL6721655 | 0.79 | MAOB (1.00) | MAOBMAOACREBBP | |
| SCHEMBL31414465 | 0.79 | MAOB (1.00) | MAOBMAOACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008145398-A1 | 4-ARYLPYRROLE SUBSTITUTED 2-INDOLINE DERIVATIVES ACTIVE AS PROTEIN KINASE INHIBITORS | PFIZER ITALIA S.R.L. (IT) | 2008-12-04 | — | — | WO | disclosed |
| US-7186745-B2 | Indolone derivatives having vascular damaging activity | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-20040147589-A1 | Indolone derivatives having vascular damaging activity | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| EP-1370527-A1 | INDOLONE DERIVATIVES HAVING VASCULAR-DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-0912557-B1 | OXINDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002070478-A1 | INDOLONE DERIVATIVES HAVING VASCULAR-DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | WO | disclosed |
| US-6265411-B1 | ANGIOGENESIS INHIBITOR | ZENECA LIMITED (GB) | 2001-07-24 | — | — | US | disclosed |
| EP-0581939-B1 | N-SULPHONYL-2-OXOINDOLE DERIVATIVES HAVING AFFINITY FOR VASOPRESSIN AND/OR OCYTOCIN RECEPTORS | SANOFI SA (FR) | 1999-06-02 | — | — | EP | disclosed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| US-5849780-A | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present | SANOFI (FR) | 1998-12-15 | — | — | US | disclosed |
| US-5726322-A | 1-benzenesulfonyl-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present | SANOFI (FR) | 1998-03-10 | — | — | US | disclosed |
| US-5696145-A | VASOPRESSIN AND OXYTOCIN RECEPTOR | SANOFI (FR) | 1997-12-09 | — | — | US | disclosed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | disclosed |
| US-5686624-A | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-11-11 | — | — | US | disclosed |
| US-5663431-A | CHEMICAL INTERMEDIATES | SANOFI (FR) | 1997-09-02 | — | — | US | disclosed |
| US-5618833-A | USEFUL FOR TREATING OR PREVENTING VASOPRESSIN OR OXYTOCIN DEPENDANT COMPLAINTS | SANOFI (FR) | 1997-04-08 | — | — | US | disclosed |
| EP-0636608-A1 | Derivatives of 1-benzenesulfonyl-1,3-dihydro-indol-2-one, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-02-01 | — | — | EP | disclosed |
| EP-0636609-A1 | 1-Benzyl-1,3-dihydro-indol-2-one derivatives, their preparation, the pharmaceutical compositions containing them | SANOFI (FR) | 1995-02-01 | — | — | EP | disclosed |
| EP-0581939-A1 | N-SULPHONYL-2-OXOINDOLE DERIVATIVES HAVING AFFINITY FOR VASOPRESSIN AND/OR OCYTOCIN RECEPTORS | SANOFI (FR) | 1994-02-09 | — | — | EP | disclosed |
| WO-1993015051-A1 | N-SULPHONYL-2-OXOINDOLE DERIVATIVES HAVING AFFINITY FOR VASOPRESSIN AND/OR OCYTOCIN RECEPTORS | ELF SANOFI (FR) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147589-A1 | Indolone derivatives having vascular damaging activity | HYOU1, IDO1, OXER1 | MAOB 581/4885MAOA 1032/4885CREBBP 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.